Global Companion Cancer Diagnostics Market Size, Status and Forecast 2021-2027

コンパニオンがん診断の世界市場規模・現状・予測2021年-2027年

◆タイトル:Global Companion Cancer Diagnostics Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE2046
◆調査・発行会社:QYResearch
◆発行日:2021年6月
◆ページ数:95
◆レポート形式:(印刷可能)PDF / 英語
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥429,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥643,500見積依頼/購入/質問フォーム
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常2日~3日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearchの日本における正規販売代理店です。

【レポートの概要】

本調査資料では、コンパニオンがん診断の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(乳がん、肺がん、結腸直腸がん、黒色腫、胃がん)、用途別市場規模(製薬&バイオ医薬品会社、リファレンスラボ、CRO、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・コンパニオンがん診断の市場動向
・企業の競争状況、市場シェア
・コンパニオンがん診断の種類別市場規模(乳がん、肺がん、結腸直腸がん、黒色腫、胃がん)
・コンパニオンがん診断の用途別市場規模(製薬&バイオ医薬品会社、リファレンスラボ、CRO、その他)
・コンパニオンがん診断の北米市場規模2016-2027(アメリカ、カナダ)
・コンパニオンがん診断の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・コンパニオンがん診断のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・コンパニオンがん診断の中南米市場規模2016-2027(メキシコ、ブラジル)
・コンパニオンがん診断の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(F. Hoffmann-La Roche、Agilent Technologies、QIAGEN、Abbott Laboratories、Almac Group、Danaher Corporation、bioMérieuxSA、Myriad Genetics)
・結論

A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.

Market Analysis and Insights: Global Companion Cancer Diagnostics Market
The global Companion Cancer Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Companion Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Companion Cancer Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Companion Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Companion Cancer Diagnostics market.

Global Companion Cancer Diagnostics Scope and Market Size
Companion Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Companion Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer

Segment by Application
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Cancer Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Breast Cancer
1.2.3 Lung Cancer
1.2.4 Colorectal Cancer
1.2.5 Melanoma
1.2.6 Gastric Cancer
1.3 Market by Application
1.3.1 Global Companion Cancer Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Pharmaceutical & Biopharmaceutical Companies
1.3.3 Reference Laboratories
1.3.4 CROs
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Companion Cancer Diagnostics Market Perspective (2016-2027)
2.2 Companion Cancer Diagnostics Growth Trends by Regions
2.2.1 Companion Cancer Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Companion Cancer Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Companion Cancer Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Companion Cancer Diagnostics Industry Dynamic
2.3.1 Companion Cancer Diagnostics Market Trends
2.3.2 Companion Cancer Diagnostics Market Drivers
2.3.3 Companion Cancer Diagnostics Market Challenges
2.3.4 Companion Cancer Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Companion Cancer Diagnostics Players by Revenue
3.1.1 Global Top Companion Cancer Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Companion Cancer Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Companion Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Companion Cancer Diagnostics Revenue
3.4 Global Companion Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Companion Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Cancer Diagnostics Revenue in 2020
3.5 Companion Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Companion Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Companion Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Companion Cancer Diagnostics Breakdown Data by Type
4.1 Global Companion Cancer Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2022-2027)

5 Companion Cancer Diagnostics Breakdown Data by Application
5.1 Global Companion Cancer Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Companion Cancer Diagnostics Market Size (2016-2027)
6.2 North America Companion Cancer Diagnostics Market Size by Type
6.2.1 North America Companion Cancer Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Companion Cancer Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Companion Cancer Diagnostics Market Size by Type (2016-2027)
6.3 North America Companion Cancer Diagnostics Market Size by Application
6.3.1 North America Companion Cancer Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Companion Cancer Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Companion Cancer Diagnostics Market Size by Application (2016-2027)
6.4 North America Companion Cancer Diagnostics Market Size by Country
6.4.1 North America Companion Cancer Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Companion Cancer Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Companion Cancer Diagnostics Market Size (2016-2027)
7.2 Europe Companion Cancer Diagnostics Market Size by Type
7.2.1 Europe Companion Cancer Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Companion Cancer Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Companion Cancer Diagnostics Market Size by Type (2016-2027)
7.3 Europe Companion Cancer Diagnostics Market Size by Application
7.3.1 Europe Companion Cancer Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Companion Cancer Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Companion Cancer Diagnostics Market Size by Application (2016-2027)
7.4 Europe Companion Cancer Diagnostics Market Size by Country
7.4.1 Europe Companion Cancer Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Companion Cancer Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Companion Cancer Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Type
8.2.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Companion Cancer Diagnostics Market Size by Application
8.3.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Companion Cancer Diagnostics Market Size by Region
8.4.1 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Companion Cancer Diagnostics Market Size (2016-2027)
9.2 Latin America Companion Cancer Diagnostics Market Size by Type
9.2.1 Latin America Companion Cancer Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Companion Cancer Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Companion Cancer Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Companion Cancer Diagnostics Market Size by Application
9.3.1 Latin America Companion Cancer Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Companion Cancer Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Companion Cancer Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Companion Cancer Diagnostics Market Size by Country
9.4.1 Latin America Companion Cancer Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Companion Cancer Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Companion Cancer Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type
10.2.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Application
10.3.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Companion Cancer Diagnostics Market Size by Country
10.4.1 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Companion Cancer Diagnostics Introduction
11.2.4 Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.2.5 Agilent Technologies Recent Development
11.3 QIAGEN
11.3.1 QIAGEN Company Details
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN Companion Cancer Diagnostics Introduction
11.3.4 QIAGEN Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.3.5 QIAGEN Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Companion Cancer Diagnostics Introduction
11.4.4 Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.4.5 Abbott Laboratories Recent Development
11.5 Almac Group
11.5.1 Almac Group Company Details
11.5.2 Almac Group Business Overview
11.5.3 Almac Group Companion Cancer Diagnostics Introduction
11.5.4 Almac Group Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.5.5 Almac Group Recent Development
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Details
11.6.2 Danaher Corporation Business Overview
11.6.3 Danaher Corporation Companion Cancer Diagnostics Introduction
11.6.4 Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.6.5 Danaher Corporation Recent Development
11.7 bioMérieuxSA
11.7.1 bioMérieuxSA Company Details
11.7.2 bioMérieuxSA Business Overview
11.7.3 bioMérieuxSA Companion Cancer Diagnostics Introduction
11.7.4 bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.7.5 bioMérieuxSA Recent Development
11.8 Myriad Genetics
11.8.1 Myriad Genetics Company Details
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Companion Cancer Diagnostics Introduction
11.8.4 Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2016-2021)
11.8.5 Myriad Genetics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Companion Cancer Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Breast Cancer
Table 3. Key Players of Lung Cancer
Table 4. Key Players of Colorectal Cancer
Table 5. Key Players of Melanoma
Table 6. Key Players of Gastric Cancer
Table 7. Global Companion Cancer Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Companion Cancer Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Companion Cancer Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Companion Cancer Diagnostics Market Share by Regions (2016-2021)
Table 11. Global Companion Cancer Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Companion Cancer Diagnostics Market Share by Regions (2022-2027)
Table 13. Companion Cancer Diagnostics Market Trends
Table 14. Companion Cancer Diagnostics Market Drivers
Table 15. Companion Cancer Diagnostics Market Challenges
Table 16. Companion Cancer Diagnostics Market Restraints
Table 17. Global Companion Cancer Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Companion Cancer Diagnostics Market Share by Players (2016-2021)
Table 19. Global Top Companion Cancer Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Companion Cancer Diagnostics as of 2020)
Table 20. Ranking of Global Top Companion Cancer Diagnostics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Companion Cancer Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Companion Cancer Diagnostics Product Solution and Service
Table 24. Date of Enter into Companion Cancer Diagnostics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Companion Cancer Diagnostics Revenue Market Share by Type (2016-2021)
Table 28. Global Companion Cancer Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Companion Cancer Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Companion Cancer Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Companion Cancer Diagnostics Revenue Market Share by Application (2016-2021)
Table 32. Global Companion Cancer Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Companion Cancer Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Companion Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Companion Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Companion Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Companion Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Companion Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Companion Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Companion Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Companion Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Companion Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Companion Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Companion Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Companion Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Companion Cancer Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Companion Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Companion Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Companion Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Companion Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Companion Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Companion Cancer Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Companion Cancer Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 64. F. Hoffmann-La Roche Company Details
Table 65. F. Hoffmann-La Roche Business Overview
Table 66. F. Hoffmann-La Roche Companion Cancer Diagnostics Product
Table 67. F. Hoffmann-La Roche Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 68. F. Hoffmann-La Roche Recent Development
Table 69. Agilent Technologies Company Details
Table 70. Agilent Technologies Business Overview
Table 71. Agilent Technologies Companion Cancer Diagnostics Product
Table 72. Agilent Technologies Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 73. Agilent Technologies Recent Development
Table 74. QIAGEN Company Details
Table 75. QIAGEN Business Overview
Table 76. QIAGEN Companion Cancer Diagnostics Product
Table 77. QIAGEN Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 78. QIAGEN Recent Development
Table 79. Abbott Laboratories Company Details
Table 80. Abbott Laboratories Business Overview
Table 81. Abbott Laboratories Companion Cancer Diagnostics Product
Table 82. Abbott Laboratories Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 83. Abbott Laboratories Recent Development
Table 84. Almac Group Company Details
Table 85. Almac Group Business Overview
Table 86. Almac Group Companion Cancer Diagnostics Product
Table 87. Almac Group Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 88. Almac Group Recent Development
Table 89. Danaher Corporation Company Details
Table 90. Danaher Corporation Business Overview
Table 91. Danaher Corporation Companion Cancer Diagnostics Product
Table 92. Danaher Corporation Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 93. Danaher Corporation Recent Development
Table 94. bioMérieuxSA Company Details
Table 95. bioMérieuxSA Business Overview
Table 96. bioMérieuxSA Companion Cancer Diagnostics Product
Table 97. bioMérieuxSA Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 98. bioMérieuxSA Recent Development
Table 99. Myriad Genetics Company Details
Table 100. Myriad Genetics Business Overview
Table 101. Myriad Genetics Revenue in Companion Cancer Diagnostics Business (2016-2021) & (US$ Million)
Table 102. Myriad Genetics Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Companion Cancer Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. Breast Cancer Features
Figure 3. Lung Cancer Features
Figure 4. Colorectal Cancer Features
Figure 5. Melanoma Features
Figure 6. Gastric Cancer Features
Figure 7. Global Companion Cancer Diagnostics Market Share by Application: 2020 VS 2027
Figure 8. Pharmaceutical & Biopharmaceutical Companies Case Studies
Figure 9. Reference Laboratories Case Studies
Figure 10. CROs Case Studies
Figure 11. Others Case Studies
Figure 12. Companion Cancer Diagnostics Report Years Considered
Figure 13. Global Companion Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Companion Cancer Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Companion Cancer Diagnostics Market Share by Regions: 2020 VS 2027
Figure 16. Global Companion Cancer Diagnostics Market Share by Regions (2022-2027)
Figure 17. Global Companion Cancer Diagnostics Market Share by Players in 2020
Figure 18. Global Top Companion Cancer Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Companion Cancer Diagnostics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Companion Cancer Diagnostics Revenue in 2020
Figure 20. Global Companion Cancer Diagnostics Revenue Market Share by Type (2016-2021)
Figure 21. Global Companion Cancer Diagnostics Revenue Market Share by Type (2022-2027)
Figure 22. North America Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Companion Cancer Diagnostics Market Share by Type (2016-2027)
Figure 24. North America Companion Cancer Diagnostics Market Share by Application (2016-2027)
Figure 25. North America Companion Cancer Diagnostics Market Share by Country (2016-2027)
Figure 26. United States Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Companion Cancer Diagnostics Market Share by Type (2016-2027)
Figure 30. Europe Companion Cancer Diagnostics Market Share by Application (2016-2027)
Figure 31. Europe Companion Cancer Diagnostics Market Share by Country (2016-2027)
Figure 32. Germany Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Companion Cancer Diagnostics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Companion Cancer Diagnostics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Companion Cancer Diagnostics Market Share by Region (2016-2027)
Figure 42. China Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Companion Cancer Diagnostics Market Share by Type (2016-2027)
Figure 50. Latin America Companion Cancer Diagnostics Market Share by Application (2016-2027)
Figure 51. Latin America Companion Cancer Diagnostics Market Share by Country (2016-2027)
Figure 52. Mexico Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Companion Cancer Diagnostics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Companion Cancer Diagnostics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Companion Cancer Diagnostics Market Share by Country (2016-2027)
Figure 58. Turkey Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Companion Cancer Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. F. Hoffmann-La Roche Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 62. Agilent Technologies Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 63. QIAGEN Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 64. Abbott Laboratories Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 65. Almac Group Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 66. Danaher Corporation Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 67. bioMérieuxSA Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 68. Myriad Genetics Revenue Growth Rate in Companion Cancer Diagnostics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[コンパニオンがん診断の世界市場規模・現状・予測2021年-2027年] (Global Companion Cancer Diagnostics Market Size, Status and Forecast 2021-2027 / QY21JNE2046)についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆